Drugs / IKS03
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05365659 | Sep 2023 → Sep 2026 overdue | diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma | Iksuda Therapeutics Ltd. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2025-05-30 | Iksuda Therapeutics Ltd. | Iksuda Therapeutics announces first patient successfully dosed in phase 1 trial evaluating IKS03 in advanced B cell non-Hodgkin lymphomas iksuda.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IKS03 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05365659 ↗ |
| Modality | Monoclonal antibody | “human monoclonal antibody (Ab)” NCT05365659 ↗ |
| Route | Intravenous | “by intravenous (IV) infusions” NCT05365659 ↗ |
| Target | CD19 | “targeting CD19” NCT05365659 ↗ |